Clinical trial
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an…
NCT00288028 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00288028 |
|---|---|
| Title | Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant |
| Official title | A Phase I Study of Bortezomib During Maintenance Phase After High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 15 |
| Start date | Jul 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Jun 1, 2012 |
| First posted | Feb 7, 2006 |
| Last update posted | Nov 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: